Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

      https://vectorscience.co/ (PRNewsfoto/Vector Sciences & Therapeutics)

      News provided by

      Vector Sciences & Therapeutics

      May 13, 2026, 10:48 ET

      Share this article

      Share this article


      Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations

      MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced it has entered into an option agreement to purchase up to a 15% equity interest in LyoGenesis Plus for cash payments over time, from treasury for of up to US$1,000,000 (the "Option"). The option is exercisable over a three-year period. LyoGenesis Plus has entered into an agreement to acquire MPP Group LLC ("MPP"), an FDA-registered, cGMP-compliant contract development and manufacturing organization headquartered in Mequon, Wisconsin. If exercised in its entirety over the three years, the Option would give Vector a 15% ownership interest in MPP, securing a long-term pharmaceutical-grade manufacturing platform for Vector's growing portfolio of peptide formulations and drug delivery products.

      Key Highlights

      • FDA-Registered, cGMP Manufacturing — MPP operates a modern 35,000 sq. ft. facility in Mequon, Wisconsin, equipped with sophisticated analytical instrumentation. The Option gives Vector an ownership stake through LyoGenesis in this infrastructure without the cost or time required to build a comparable facility.

      • 22 Novel Peptide Formulations — Vector and MPP will jointly develop shelf-stable peptide formulations with a target stability of up to 24 months, including 14 peptides recently removed from the FDA Category 2 list.

      • Capital Leverage Through LyoGenesis Plus — LyoGenesis Plus is well-capitalized with a $2 million equipment line of credit and a $1 million accounts receivable facility, giving Vector non-dilutive access to expansion capital as manufacturing needs grow.

      "Ownership of an FDA-registered, cGMP manufacturing facility is foundational for any company serious about delivering pharmaceutical-grade therapeutics," said Tommy Thompson, Chairman of Vector Science & Therapeutics and former U.S. Secretary of Health and Human Services. "This Option gives Vector a credible, long-term manufacturing platform from which to build its peptide portfolio and deliver pharmaceutical-grade products to physicians."

      Key Elements Supporting Exercise of the Option

      • The Option — Vector has the right to acquire up to a 15% equity interest in LyoGenesis Plus for a cumulative cash investment, from its treasury, of up to US$1,000,000, exercisable at any time over a three-year period. This structure allows Vector to invest incrementally in line with its business growth and preserve treasury and cashflow.

      • MPP Facility — Through its equity position in LyoGenesis Plus, Vector gains an ownership stake in MPP's FDA-registered, cGMP-compliant manufacturing facility in Mequon, Wisconsin, without the cost or timeline required to build equivalent infrastructure.

      • LyoGenesis Plus — LyoGenesis Plus was founded by Tommy Thompson and Bill Jackson to acquire and consolidate pharmaceutical services companies. Following its acquisition of MPP, LyoGenesis Plus intends to continue seeking additional CDMOs across North America as part of its long-term growth strategy.

      "Controlling our manufacturing platform is critical to our long-term success in the peptide market," said Bill Jackson, Chief Executive Officer of Vector Science & Therapeutics. "LyoGenesis Plus and MPP give us a pharmaceutical-grade foundation — not research-grade — from which to supply physicians with novel, shelf-stable peptide formulations as that $80.8 Billion market continues to grow." (Grandview Research) (https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market)

      Tommy Thompson, Chairman of Vector, and Bill Jackson, Chief Executive Officer of Vector, are minority owners in LyoGenesis Plus, together holding less than 50% of its equity. Both individuals declared their conflicts of interest and recused themselves from the Vector board vote approving this transaction.

      Regulatory and Exchange Matters

      The grant and exercise of the Option does not constitute a "related party transaction" as defined under Multilateral Instrument 61-101: Protection of Minority Securityholders in Special Transactions ("MI 61-101"), as related parties of Vector do not own more than 50% of the equity securities of LyoGenesis Plus. In any event, even if the transaction were considered a related party transaction, the Company would rely on the exemptions from the valuation and minority shareholder approval requirements set out in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the Option nor the shares issuable upon its exercise exceeds 25% of Vector's market capitalization.

      The exercise of the Option is a Reviewable Transaction under TSXV Policy 5.3 — Acquisitions and Dispositions of Non-Cash Assets — due to the involvement of Non-Arm's Length Parties. The Option cannot be exercised until TSXV conditional approval has been received, all required documentation has been submitted, and all closing conditions have been satisfied.

      The TSXV has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this news release.

      Pharmaceutical-Grade vs. Research-Grade Peptides

      Pharmaceutical-grade (also called medical-grade) peptides are manufactured under the U.S. Food and Drug Administration's current Good Manufacturing Practices (cGMP) in FDA-registered facilities. They are tested to defined specifications for identity, purity, potency, sterility, and endotoxins, and they are intended for use in humans under physician supervision.

      Research-grade peptides, by contrast, are produced for laboratory study only. They are typically labeled "for research use only" or "not for human use," are not manufactured to pharmaceutical quality or sterility standards and are not regulated for therapeutic application.

      Under this agreement, Vector and MPP will jointly develop and manufacture pharmaceutical-grade peptides intended exclusively for physician-supervised therapeutic use.

      About Vector Science & Therapeutics

      Vector Science & Therapeutics, Inc., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares are listed on the TSX Venture Exchange under the symbol PAIN. For more information, visit www.vectorscience.co.

      About MPP Group LLC

      MPP Group LLC is a contract development and manufacturing organization headquartered in Mequon, Wisconsin, operating an FDA-registered drug manufacturing facility with cGMP-compliant aseptic capabilities. MPP serves clients across pharmaceutical formulation development, analytical method development, and small- to mid-scale aseptic manufacturing.

      Forward-Looking Statements

      This news release contains forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the development and manufacturing of peptide formulations, the commencement and timing of formulation and manufacturing activities, capital expenditure expectations, market size, and the Company's commercialization strategy. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Vector Science & Therapeutics undertakes no obligation to update these statements, except as required by applicable law.

      Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

      SOURCE Vector Sciences & Therapeutics

      Modal title

      Also from this source

      Vector Science and Therapeutics Corp. Responds to HHS Secretary Kennedy's Call for a Regulated Peptide Marketplace

      Vector Science and Therapeutics Corp. Responds to HHS Secretary Kennedy's Call for a Regulated Peptide Marketplace

      Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today welcomed remarks by U.S. Health and Human Services Secretary...

      Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides

      Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides

      Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today introduced its investigational peptide-matrix microneedle...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Acquisitions, Mergers and Takeovers

      Acquisitions, Mergers and Takeovers

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.